Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia.

Abstract

In this study, the availability of an HLA-identical sibling donor was not associated with a better survival rate because of both the impossibility of some patients with a donor to receive BMT and the more efficient salvage treatment of patients who relapsed after intensive consolidation chemotherapy than of patients who relapsed after BMT.

The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921)

“…Several reports studied the same issue in primary AML. 31,32 In order to answer the question as to whether allogeneic transplantation was superior or not compared to autologous transplantation or chemotherapy as postremission therapy, the Leukemia Party of the European Group for BMT registered patients from the time of HLA typing on an intention-to-treat basis. 29 Of 26 patients with a donor, 22 (85%) were allografted.…”

Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement

“…1-3 Similarly, the majority of patients with acute myeloid leukemia (AML), regardless of their age, can achieve a complete remission (CR) using combined chemotherapy with anthracyclines, cytosine arab- inoside, etoposide, carboplatinum and other drugs in different combinations. [4][5][6] However, many of these AML patients and high-risk ALL patients will never be cured with chemotherapy due to the high incidence of relapse. 5,6 Bone marrow transplantation (BMT) technologies have improved significantly over the past 15-20 years and now constitute a regular therapeutic approach for poor-risk ALL patients.…”

“…[4][5][6] However, many of these AML patients and high-risk ALL patients will never be cured with chemotherapy due to the high incidence of relapse. 5,6 Bone marrow transplantation (BMT) technologies have improved significantly over the past [15][16][17][18][19][20] years and now constitute a regular therapeutic approach for poor-risk ALL patients.…”

“…[4][5][6] However, many of these AML patients and high-risk ALL patients will never be cured with chemotherapy due to the high incidence of relapse. 5,6 Bone marrow transplantation (BMT) technologies have improved significantly over the past [15][16][17][18][19][20] years and now constitute a regular therapeutic approach for poor-risk ALL patients. 7,8 Although allogeneic BMT is currently curative for approximately 50% of the patients, [8][9][10][11][12] unfortunately, this kind of transplant can only be applied to those patients having an HLA-identical donor, either family related or unrelated.…”

The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer

“…In these series, the cure rate with marrow transplantation has ranged from 40 to 64 percent, while that for chemotherapy has ranged from 19 to 24 percent. [101][102][103][104][105][106][107][108][109][110][111][112][113][114][115] However, there have been important advances in both chemotherapy and transplantation since the conduct of most of these studies. Further, it remains untested whether a strategy of transplantation in first remission is superior to the combination of initial chemotherapy followed by transplantation as salvage therapy.…”